通用型人类多能干细胞来源胰岛类器官糖尿病根治性疗法 (Off-the-shelf Stem Cell-derived Islet Organoid Therapy for Diabetes Cure)

一、企业概况与使命愿景 | Company Overview & Mission

周易生物醫藥科技（香港）有限公司（Nordia Biotech）是由香港大学医学院周中军教授领衔创立的前沿生物科技企业。公司立足香港、依托大湾区与长三角产业生态，专注于新一代通用型人类多能干细胞来源胰岛类器官（SC-islets）的开发，致力于攻克困扰全球数亿患者的慢性代谢性疾病，为全球患者提供兼具根治潜力、高安全性与可负担性的突破性细胞疗法。

Nordia Biotech & Pharmaceuticals HK Ltd is a pioneering biotech venture founded by Prof. Zhongjun Zhou from the Faculty of Medicine, The University of Hong Kong (HKU). Anchored in Hong Kong and leveraging the biopharma ecosystem of the Greater Bay Area and Yangtze River Delta, Nordia specializes in next-generation universal human pluripotent stem cell-derived islet organoids (SC-islets). Our mission is to deliver curative, safe, and scalable cell therapies for hundreds of millions of diabetes patients worldwide.

二、突破性技术亮点与科学壁垒 | Core Breakthroughs & Scientific Edge

公司拥有全球首创的人多能干细胞“自发形成 3D 结构”胰岛类器官生产平台，高度模拟天然胰岛的器官形态发生过程。通过自主开发的无异种成分（AOF）与化学成分限定（CD）细胞外基质（ECM）微环境，从源头消除了动物源病原风险与批次波动。同时，团队在国际顶级期刊《Cell Stem Cell》发表的创新成果——人源富含 VI 型胶原蛋白生物材料支架，可在共移植后迅速诱导微血管网络重建，根本性解决了类器官移植后细胞存活率低和血管化不良的国际技术难题。

We have established the world’s first production platform enabling spontaneous 3D morphogenesis of SC-islets, closely recapitulating natural human islet development. By deploying an animal origin-free (AOF) and chemically-defined (CD) extracellular matrix (ECM), our system completely eliminates pathogen contamination risks and batch variability. Furthermore, our proprietary pro-angiogenic scaffold published in Cell Stem Cell rapidly promotes microvascular network infiltration upon co-transplantation, overcoming the critical global hurdles of poor cell engraftment and ischemic death.

三、对标竞品的绝对竞争优势 | Definitive Competitive Edge vs. Global Peers

相较于国际领跑者（如 Vertex VX-880）及国内早期悬浮培养产品，周易生物具备显著的技术与产业壁垒：

1. 细胞存活与活性优势：传统“消化-重聚”工艺会导致超 50% 的细胞应激死亡与去分化，周易自发形成技术完整保留了细胞间通信与基质互作，高糖刺激胰岛素分泌（GSIS）活性显著领先。

2. 极简工艺与成本优势：全封闭、自发成型工艺大幅缩减复杂设备与耗材投入，生产成本显著低于同类竞品，赋予终端商业化广阔的定价空间。

Compared with global frontrunners (e.g., Vertex’s VX-880) and conventional 2D/3D suspension competitors, Nordia delivers distinct competitive moats:

1. Superior Viability & Functionality: Unlike conventional "dissociation-reaggregation" methods that cause over 50% cell loss and functional impairment, our spontaneous 3D formation preserves intact cell-cell and cell-matrix communications, yielding superior glucose-stimulated insulin secretion (GSIS) responsiveness.

2. Simplified Biomanufacturing & Cost Efficiency: The streamlined, xeno-free manufacturing process significantly slashes production costs, providing substantial commercial margin advantages.

四、政府权威资助背书与产业协同 | Government Validation & RAISe+ Backing

项目的颠覆性创新与产业化可行性获得了香港特区政府与学术界的高度认可，成功入选香港创新科技署（ITC）旗舰级「产学研1+计划」。叠加此前获得的港大 TSSSU+、香港科技园 Incu-Bio 培育计划及香港 X 科技基金投资，公司已在香港科学园设立国际研发中心，并在苏州工业园区 BioBAY 设立全资子公司推进中试转化，构建了“香港原创研发 + 内地转化放大与临床验证”的高效协同布局。

Our scientific excellence and commercial viability are rigorously validated by the Hong Kong SAR Government, having been awarded funding under the prestigious RAISe+ Scheme by the Innovation and Technology Commission. Complementing previous backing from HKU TSSSU+, HKSTP Incu-Bio Programme, and Hong Kong X Technology Fund, we have established operations across HK Science Park and Suzhou BioBAY, creating a robust synergy between Hong Kong's deep tech R&D and Mainland China's clinical translational scale.

五、临床潜力与商业化变现路径 | Clinical Potential & Revenue Streams

在临床转化方面，公司已与上海长海医院达成深度合作，针对 3c 型胰腺炎继发糖尿病及 1 型糖尿病启动研究者发起临床试验（IIT），未来将进一步拓展至香港本地及港大深圳医院。

For clinical development, Nordia has entered into a strategic collaboration with Shanghai Changhai Hospital to initiate Investigator-Initiated Trials (IIT) for pancreatogenic Type 3c diabetes and Type 1 diabetes, with expanded plans across HKU-SZ Hospital and local Hong Kong medical hubs.

六、融资意向与全球 BD 合作机遇 | Investment & Global BD Opportunities Sought

公司当前投后估值已达 2 亿港币。借助「一带一路」高峰论坛，我们诚寻以下两类战略合作伙伴：

1. 股权融资（Pre-A / A 轮）：计划融资 3,000 万至 5,000 万港币，专项用于食蟹猴前临床安全性最终验证、GMP 标准产线及临床试验推进。

2. 全球 BD 与商业授权：寻求与全球知名药企（如礼来、诺和诺德、勃林格殷格翰等）洽谈管线海外授权（Licensing-out）、联合开发或设立海外 NewCo；同时寻求与东南亚、中东等“一带一路”沿线高端医疗机构合作，共建跨境细胞治疗与医疗旅游中心。

With a current post-money valuation of HK$200 million, Nordia invites global investors and biopharma leaders to explore strategic partnerships:

1. Equity Financing (Pre-A / A Round): Raising HK$30–50 million to fund primate GLP preclinical validation, GMP facility, and clinical trials.

2. Global BD & Licensing: Seeking out-licensing, co-development, and overseas NewCo partnerships with multinational pharma leaders (e.g., Novo Nordisk, Eli Lilly); and inviting premium healthcare networks across Southeast Asia and the Middle East to co-establish international cell therapy centers.